Small Molecule for MS
Total Trials
7
As Lead Sponsor
As Collaborator
0
Total Enrollment
398
NCT04462198
Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss
Phase: Phase 1/2
Role: Lead Sponsor
Start: Oct 15, 2020
Completion: Jun 17, 2021
NCT04725175
Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers
Phase: Phase 1
Start: Feb 26, 2021
Completion: Sep 1, 2021
NCT04941781
PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers
Start: Sep 1, 2021
Completion: Nov 10, 2021
NCT05983939
Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers
Start: Jun 26, 2023
Completion: Feb 1, 2024
NCT06083753
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
Phase: Phase 2
Start: Nov 6, 2023
Completion: Aug 4, 2025
NCT06683612
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
Start: Dec 9, 2024
Completion: Jun 12, 2025
NCT06810245
Study of PIPE-791 for Subjects with Chronic Osteoarthritis Pain or Chronic Low Back Pain
Start: Feb 4, 2025
Completion: Feb 15, 2026
Loading map...